Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00105183 · ClinicalTrials.gov registry record · Phase 3
EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection
A Phase 3 study, sponsored by Neovii Biotech.
- Completed
- Registry status
- Phase 3
- Development phase
- 223
- Enrollment target
NCT00105183 is a Phase 3 study that has completed, run by Neovii Biotech. The registered enrollment target is 223 participants.
The verdict
NCT00105183, a Phase 3 study, has completed, sponsored by Neovii Biotech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 223 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of the study drug, known as "ATG Fresenius S," which is sometimes called "EZ-2053," to prevent a lung transplant patient's body from rejecting a transplanted lung or lungs.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL EZ-2053
- BIOLOGICAL EZ-2053 5mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 223 participants |
| Start Date | 2005-01 |
| Est. Completion | 2011-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00105183
The ClinicalTrials.gov registry entry for NCT00105183 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 223 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neovii Biotech, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00105183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00105183 about?
NCT00105183 is a clinical study titled "EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection". The purpose of this study is to assess the efficacy and safety of the study drug, known as "ATG Fresenius S," which is sometimes called "EZ-2053," to prevent a lung transplant patient's body from rejecting a transplanted lung or lungs.
What is the current status of trial NCT00105183?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 223 participants. The study started on 2005-01. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00105183?
The interventions under investigation include: Placebo (BIOLOGICAL), EZ-2053 (BIOLOGICAL), EZ-2053 5mg/kg (BIOLOGICAL).
Who is sponsoring clinical trial NCT00105183?
This trial is sponsored by Neovii Biotech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.